Introduction
Alternative splicing allows the generation of different protein isoforms from initially identical transcripts. Recent studies indicate that more than 90% of multiexon human genes are subject to alternative splicing, the majority of which exhibit tissue-specific splicing patterns. 1, 2 The dysregulation of alternative splicing has been implicated in the pathogenesis of several diseases, including cancer and muscular dystrophy. 3 Disruption of the normal activity of the alternative splicing regulator muscleblind-like 1 (MBNL1) has been identified as a key contributor to the pathogenesis of myotonic dystrophy (dystrophia myotonica, DM). DM is an inherited, autosomal dominant disorder caused by the expression of transcripts from the DMPK (DM1) or ZNF9 (DM2) gene containing expanded CUG or CCUG repeats, respectively. [4] [5] [6] [7] These expanded repeat-containing RNAs accumulate in nuclear foci that bind MBNL1, and it has been proposed that loss of MBNL1 activity due to sequestration is a primary cause of DM pathogenesis. [8] [9] [10] [11] Consistent with this hypothesis, the alternative splicing of conserved developmental alternative splicing of muscleblind-like (MBNL) transcripts regulates MBNL localization and activity Fulvia Terenzi 1 and Andrea N. Ladd 1,2, several MBNL1 targets is disrupted in DM patient samples and mouse models. 12 Both splicing changes typical of DM and myotonia, a hallmark of the disease, are also present in mice deficient in MBNL1. 12, 13 Furthermore, expression of exogenous MBNL1 was sufficient to restore normal alternative splicing patterns and rescue myotonia in a mouse model of DM.
14 Another splicing factor, CUG binding protein 1 (CUG-BP1), antagonizes the effects of MBNL1 on the alternative splicing of at least some of these transcripts and is upregulated in DM1 tissues. [15] [16] [17] [18] Overexpression of CUG-BP1 in transgenic mice recapitulates aberrant splicing patterns and features of the myopathy seen in DM1. 19 CUG-BP1 has not been found to be upregulated in DM2, however, which is usually phenotypically less severe than DM1. 12 Interestingly, the splicing patterns observed in adult DM patient heart and muscle tissues resemble normal splicing patterns in these tissues at fetal stages. 12, 17, 20 DM is therefore thought to be caused by dysregulation of developmental stage-specific alternative splicing. MBNL1 has been implicated in regulating fetal-to-adult transitions in alternative splicing during normal Muscleblind-like (MBNL) proteins have been shown to regulate pre-mRNA alternative splicing, and MBNL1 has been implicated in regulating fetal-to-adult transitions in alternative splicing in the heart. MBNL1 is highly conserved, exhibiting more than 95% identity at the amino acid level between birds and mammals. To investigate MBNL1 expression during embryonic heart development, we examined MBNL1 transcript and protein expression in the embryonic chicken heart from the formation of the primitive heart tube through cardiac morphogenesis (embryonic days 1.5 through 8). MBNL1 transcript levels remained steady throughout these stages, whereas MBNL1 protein levels increased and exhibited a shift in isoforms. MBNL1 has several alternatively spliced exons. Using RT-PcR, we determined that the inclusion of one of these, exon 5, decreases dramatically during cardiac morphogenesis. This developmental transition is conserved in mice. Functional analyses of MBNL1 isoforms containing or lacking exon 5-encoded sequences revealed that exon 5 is important for the regulation of the subcellular localization, RNA binding affinity, and alternative splicing activity of MBNL1 proteins. A second MBNL protein, MBNL2, is also expressed in the embryonic heart. We found that MBNL2 exon 5, which is paralogous to MBNL1 exon 5, is similarly regulated during embryonic heart development. Analysis of MBNL1 and MBNL2 transcripts in several embryonic tissues in chicken and mouse indicate that exon 5 alternative splicing is highly conserved and tissue-specific. Thus, we propose that conserved developmental stage-and tissue-specific alternative splicing of MBNL transcripts is an important mechanism by which MBNL activity is regulated during embryonic development. regulated in MBNL2 transcripts during heart development, and the extent of inclusion of exon 5 in both MBNL1 and MBNL2 transcripts varies in different embryonic tissues. The high degree of conservation of exon 5 alternative splicing indicates that regulation of this exon is an important mechanism by which MBNL function is modulated in vivo.
Results

MBNL1 protein expression is dynamic in the embryonic heart.
Previous studies have detected strong MBNL1 expression in both late embryonic and adult hearts by western blotting, and MBNL1 has been implicated in regulating conserved fetal-toadult changes in alternative splicing of cardiac transcripts during postnatal maturation of the heart in birds and mammals. 21, 22 In order to determine whether MBNL1 expression changes during early embryonic heart development, we performed semi-quantitative RT-PCR and western blot analyses to measure MBNL1 transcript and protein levels in embryonic chicken hearts over a time course of development. Stages for the time course were chosen to bracket cardiac morphogenesis, beginning with the newly formed primitive heart tube at embryonic day 1.5 (d1.5, Hamburger & Hamilton stage 10), and ending with embryonic day 8 (Hamburger & Hamilton stage 35), when cardiac morphogenesis is essentially complete; day 8 is the earliest stage examined in previous studies. PCR primers were designed to recognize all known MBNL1 variants. MBNL1 transcripts were detected in the embryonic heart at all stages examined, and transcript levels did not change appreciably during cardiac morphogenesis (Fig.  1A) . In contrast, MBNL1 protein levels were not detectable until embryonic day 2, and increased significantly over time (Fig. 1B) . A similar increase was observed using the monoclonal antibody 3A4 against MBNL1 (data not shown).
Interestingly, in addition to an increase in the overall level of MBNL1 protein, there is also a shift in MBNL1 isoform expression during embryonic heart development (Fig. 1B) . Two MBNL1 protein isoforms were detected in the embryonic heart. At embryonic day 2, the slower migrating MBNL1 isoform (black arrow) is predominant. By embryonic day 4 the isoforms are present in approximately equivalent portions, and at later stages the faster migrating isoform (grey arrow) becomes predominant. MBNL1 protein isoforms ranging in size from 35 to 42 kDa have been reported in human cells, and are thought to be generated at least in part by differential splicing of MBNL1 transcripts. 9, 24 Alternative splicing of MBNL1 exon 5 undergoes a conserved shift during embryonic heart development. Alignments of human MBNL1 cDNAs, expressed sequence tags, and genomic sequences have lead to the identification of at least nine different MBNL1 protein isoforms generated by alternative splicing.
25
MBNL1 transcripts contain several alternatively spliced exons. The numbers assigned to specific exons vary in the literature; in this paper, we use the exon numbering system of Pasqual and colleagues. 25 Transcripts lacking exon 3, a 204 nt exon that encodes a large portion of the linker region between two pairs of zinc fingers that mediate RNA binding, have been found in both human and mouse. Skipping of exons 5 and 7 generate in-frame deletions heart development. 21, 22 These splicing transitions are thought to contribute to the reprogramming of gene expression during postnatal maturation of the heart. Gene expression is potentially even more dynamic during embryonic heart development. The heart is the first organ to develop in the embryo, forming initially as a simple beating tube. The heart undergoes extensive morphogenesis during early embryonic life, transforming from a simple, beating tube into a septated, four-chambered pump with valves to prevent bidirectional flow. Cardiac looping, trabeculation and compaction of the ventricular wall, endocardial cushion formation and remodeling during septation and valvulogenesis, and migration and invasion of cardiac neural crest cells during cardiac morphogenesis all contribute to the architecture of the mature heart. 23 Although changes in cell fate and function during cardiac morphogenesis have been extensively studied, the roles of alternative splicing regulators during embryonic heart development have so far remained largely unexplored.
In this study, we investigated the expression of MBNL1 in the heart during embryonic development. We found that MBNL1 expression is dynamic during cardiac morphogenesis. In particular, the alternative splicing of MBNL1 exon 5 shifts to predominantly exon skipping during cardiac morphogenesis, a transition that is conserved in chicken and mouse hearts. Functional analyses of MBNL1 protein isoforms containing or lacking the region encoded by exon 5 revealed that this domain is important for MBNL1 subcellular localization, RNA binding affinity, and alternative splicing activity. The paralogous exon 5 is similarly the nine human MBNL1 variants. 25 There is also a high degree of sequence conservation in the alternative exons. The chicken exons 3, 5, 7 and 8 are 73%, 100%, 100% and 99% identical, respectively, to the orthologous human exons at the nucleotide level, and the sequences they encode are 96-100% identical at the amino acid level.
To determine whether these exons are alternatively spliced in the developing heart, we performed RT-PCR analyses to measure the extent of exon inclusion in embryonic chicken hearts at different stages of development. Exon 3 is predominantly included at all stages examined (Fig. 2B) . Exons 7 and 8 are variably included in cardiac MBNL1 transcripts, but the extent of inclusion for each changes very little during development (Fig. 2C) ; exon 7 is mostly skipped at all stages, whereas exon 8 is largely included. In contrast, exon 5 undergoes a strong change in alternative splicing of 18 and 12 amino acids, respectively, whereas skipping of the 95 nt exon 8 results in a frame shift and the insertion of a premature termination codon that replaces 50 amino acids at the C-terminus of the protein with ten unrelated residues. Alignment of chicken MBNL1 cDNA and expressed sequence tag sequences to chicken chromosome 9 revealed that the genomic structure of MBNL1 is highly conserved between chickens and mammals ( Fig. 2A) . Although gaps in the genomic sequence from the available chicken reference assembly (accession number NC_006096.2) prevent comparison of the 5' ends of the chicken and human MBNL1 genes, the exon structure of the coding region, which begins in exon 2, is strikingly similar. Exons 2 through 8 and exon 10 are the same size and relative position in the chicken and human genes. No evidence was found for a chicken ortholog of exon 9, which is included in only one of protein (GFP) was fused to the N-terminus of exon 5-containing (GFP-MBNL1) or -lacking (GFP-MBNL1-D5) chicken MBNL1 isoforms and transfected into chicken primary embryonic cardiomyocytes. Western blotting with an anti-GFP antibody confirmed the proteins expressed from these plasmids were the expected sizes (data not shown). Similar to what Lin et al. reported, GFP-MBNL1 is predominantly found in the nucleus, whereas GFP-MBNL1-D5 is found in both the nucleus and cytoplasm (Fig. 4A) .
To confirm that the effect of exon 5 on MBNL1 localization is general and not cell type-specific, we also transfected GFP-MBNL1 and GFP-MBNL1-D5 into COS-M6 cells, a monkey kidney fibroblast-like cell line (Fig. 4B) . Similar to the results of Lin et al. in skeletal muscle cells and our results in cardiomyocytes, GFP-MBNL1 was found only in the nucleus in COS-M6 cells, whereas GFP-MBNL1-D5 was present in the cytoplasm as well. This indicates that the differential localization of MBNL1 isoforms is not cell type-specific, and exon 5 confers a strictly nuclear localization to MBNL1 proteins in general.
Based upon these data, we predicted that the fraction of MBNL1 protein found in the nucleus would decrease during heart development as the level of exon 5 inclusion decreases. To determine whether the subcellular localization of endogenous MBNL1 proteins indeed changes during embryonic heart development, we performed western blot analyses on nuclear and cytoplasmic protein fractions collected from chicken hearts at different stages of development (Fig. 4C) . The efficacy of the fractionation was confirmed using antibodies against hnRNPC, a nuclear marker, and β-tubulin, a cytoplasmic marker, as previously described. 22 Protein integrity and equivalent loading at all stages was confirmed by Ponceau S staining. In agreement with our previous data, at early stages when exon 5 is predominantly included MBNL1 protein is found almost exclusively in the nucleus, but at later stages the fraction of MBNL1 protein in the cytoplasm increases as exon 5 inclusion decreases.
Inclusion of exon 5 affects MBNL1 RNA binding and alternative splicing activities. To date, no one has ascribed functional consequences to inclusion or skipping of exon 5 on the activities of the encoded MBNL1 protein isoforms. MBNL1 binds to RNA via its two zinc finger motifs, but analysis of MBNL1 deletion mutants in yeast three-hybrid assays has suggested that additional sequences outside of the zinc fingers affect RNA binding. 24 Deletion of the linker region between the zinc finger pairs abrogated RNA binding, whereas deletion of the C-terminus of the protein enhanced binding. 24 The 18 amino acids encoded by MBNL1 exon 5 lie downstream of the second zinc finger pair. To determine whether full length (MBNL1) and exon 5-lacking (MBNL1-D5) isoforms differ in RNA binding activities, we performed RNA-electrophoretic mobility shift assays. MBNL1 promotes cardiac troponin T (cTNT) exon 5 skipping. 16, 21 Bacterial recombinant purified MBNL1 and MBNL1-D5 proteins were incubated with a 50mer RNA probe that corresponds to nucleotides -8 to -58 in the 3'-end of the intron 4 in the human cTNT pre-mRNA. This 50mer has been shown to form a stem-loop structure that binds MBNL1 and is required for MBNL-mediated repression of cTNT exon inclusion. 26 In the gel retardation assay during heart development ( Fig. 2D) . In the primitive heart tube (d1.5), exon 5 is predominantly included. The extent of exon 5 inclusion gradually decreases during cardiac morphogenesis, such that by embryonic day 8, the majority of MBNL1 transcripts lack exon 5. The predicted size difference of isoforms containing or lacking exon 5 (~2 kDa) is consistent with the MBNL1 protein doublet observed by western blot (Fig. 1B) , although we cannot rule out the possibility that post-translational modifications also affect the migration of MBNL1 isoforms.
To confirm that the developmental change in MBNL1 exon 5 alternative splicing observed in the chicken heart is conserved in mammals, we performed RT-PCR to measure the extent of exon 5 inclusion in embryonic mouse hearts collected at similar stages of development (a mouse heart at E9 is roughly equivalent to a d2 chicken heart, an E16 mouse heart is similar to a d7 chicken heart). Although the absolute level of inclusion is somewhat different than in the chicken heart, exon 5 inclusion does indeed decrease during cardiac morphogenesis in the mouse heart as well, with exon skipping predominating in the late fetal heart (Fig. 3) .
Alternative splicing of exon 5 affects the subcellular localization of MBNL1. The high degree of conservation of both the sequence and temporal regulation of MBNL1 exon 5 in the heart from birds to mammals suggests that this exon is functionally important in vivo. Previous work has indicated that different MBNL1 isoforms are found in the nucleus and the cytoplasm in the heart in birds and mammals. 22 Lin and colleagues reported that inclusion or skipping of exon 5 (referred to in their report as exon 7) affected the nuclear/cytoplasmic distribution of human MBNL1-GFP fusion proteins in skeletal muscle cells. 12 To determine whether the effect of exon 5 inclusion similarly regulates the nuclear/cytoplasmic localization of MBNL1 proteins in chicken heart muscle cells, the open reading frame of green fluorescent from the MBNL1 and MBNL1-D5 expression plasmids, western blots were performed (Fig. 6B) . The steady state level of protein expressed from the MBNL1-D5 plasmid was consistently higher than that of the MBNL1 plasmid at comparable doses, however, illustrated in Figure 5 , we show that both purified proteins formed detectable RNP complexes with the cTNT 50-mer probe and the intensities of the retarded complexes increase in a dose-dependent manner. By measuring the ratio of bound RNA to total RNA per lane we calculated apparent K d values of 0.25 μM for MBNL1 and 0.10 μM for MBNL1-D5. Thus, the affinity of MBNL1-D5 for the cTNT probe is approximately two-and-a-half times greater than full length MBNL1. These apparent K d values are 10-to 20-fold higher than those reported for MBNL1 by some groups. It should be noted that we used the same highly stringent binding conditions used by Warf and Berglund, who reported apparent K d values for a human MBNL1 isoform lacking exon 5 ranging from 0.23 to 0.28 μM on multiple substrates; they reported that reducing the stringency by altering the salt, heparin, or temperature reduces the apparent K d values for MBNL1 proteins to those measured by others. 26 Given our results that inclusion of exon 5 regulates both MBNL1 localization and RNA binding, we next asked whether exon 5 inclusion modulates its ability to affect the alternative splicing of a target transcript. To determine whether MBNL1 isoforms containing or lacking the sequence encoded by exon 5 differ in their ability to affect alternative splicing, expression vectors for MBNL1 or MNBL1-D5 protein isoforms were co-transfected into primary chicken embryonic cardiomyocytes with the R35C minigene, which contains a heterologous alternative exon flanked by regulatory regions that modulate inclusion of the chicken cTNT alternative exon 5. 27 This minigene was previously used to demonstrate that MBNL1 promotes cTNT exon 5 skipping. 16 Co-transfection of either MBNL1 or MBNL1-D5 induced skipping of the minigene exon, indicating that both exon 5-including and -lacking MBNL1 isoforms possess inherent splicing activity (Fig. 6A) . At comparable doses of plasmid, however, exon skipping was slightly more pronounced for the exon 5-containing MBNL1 isoform. To determine whether this was due to a difference in the levels of protein expressed expressed in the heart. 9,28 MBNL2 has a very similar genomic structure to that of MBNL1, with a paralogous exon 5 that is also alternatively spliced. 25 Alignment of chicken MBNL2 cDNA (accession number NM_001081700) to the chicken MBNL2 gene on chromosome 1 (accession number NC_006088) revealed that, like MBNL1, exon sizes and positions are conserved between the chicken and mammalian MBNL2 coding regions (data not shown). To test whether MBNL2 exon 5 undergoes a developmental transition in alternative splicing similar to that seen for MBNL1 exon 5, we performed RT-PCR on RNAs from embryonic chicken hearts over the same time course of development. As observed for MBNL1, MBNL2 transcripts in the early heart tube contain exon 5 at a higher level than transcripts from later stages of heart development (Fig. 7A) . Also as observed for MBNL1, this developmental transition in MBNL2 alternative splicing is conserved in the developing mouse heart (Fig. 7B) .
To determine whether the inclusion of exon 5 in MBNL2 transcripts also affects the subcellular localization of MBNL2 protein, GFP was fused to the N-terminus of exon 5-containing (GFP-MBNL2) or -lacking (GFP-MBNL2-D5) MBNL2 isoforms and transfected into chicken primary embryonic cardiomyocytes and COS-M6 cells (Fig. 7C and D) . As we observed not lower, indicating that MBNL1-D5 is in fact a less potent inhibitor of cTNT exon inclusion than full-length MBNL1. Even though 0.3 μg of MBNL1-D5 expression plasmid produced more protein than 1.2 μg of MBNL1 plasmid, this resulted in approximately eight-fold less inhibition of cTNT exon inclusion.
These results indicate that MBNL1-D5 has less splicing activity than full length MBNL1 despite binding to the target RNA with higher affinity. This discrepancy could be explained by the cytoplasmic localization of a substantial portion of the MBNL1-D5 isoform. During heart development, however, endogenous MBNL1 retains a significant nuclear presence at later stages (Fig. 4C) . To investigate whether there is a change in endogenous MBNL1-mediated alternative splicing, the splicing patterns of endogenous cTNT transcripts were assessed by RT-PCR at different stages of heart development (Fig. 6C) . MBNL1 has been shown to be a determinative factor for repressing inclusion of both cTNT exons 4 and 5 in vivo. 21 We found that the level of inclusion of both cTNT alternative exons increased during development concomitant with the switch in MBNL1 isoform expression, which would be consistent with a decrease in endogenous MBNL1 activity.
Developmental changes in exon 5 inclusion are conserved in MBNL2. A second MBNL family member, MBNL2, is also is predominantly skipped in chicken and mouse MBNL transcripts. In embryonic brain, however, exon 5 is included to an equal or greater extent than it is skipped in MBNL1 and MBNL2 transcripts. The majority of MBNL1 transcripts skipped exon 5 in chicken and mouse livers ( Fig. 8A and C) . MBNL2 exon 5, in contrast, was predominantly included in chicken liver but predominantly skipped in mouse liver (Fig. 8B and D) . This suggests that not all developmental patterns of MBNL alternative splicing are conserved between birds and mammals, and that MBNL1 exon 5 and MBNL2 exon 5 are not always co-regulated. These data indicate that the extent of exon 5 inclusion, and thus presumably the subcellular localization and activities of MBNL proteins, is differentially regulated in different embryonic tissues.
for MBNL1, MBNL2 isoforms derived from exon 5-containing transcripts were found exclusively within the nucleus in both cardiomyocytes and COS-M6 cells, whereas exon 5-lacking isoforms were found in both the nucleus and cytoplasm. These data indicate that the regulated inclusion of exon 5 is a conserved mechanism for modulating the localization of MBNL paralogs.
The extent of MBNL1 and MBNL2 exon 5 inclusion is tissue-specific. MBNL1 and MBNL2 are broadly expressed in embryonic and adult tissues. 9, 28 To determine to what extent exon 5 is included in other embryonic tissues that express MBNL proteins, we performed RT-PCR on RNAs from chicken d14 or mouse E16 heart, skeletal muscles, brain and liver (Fig. 8) .
In breast and thigh muscles, like heart at these stages, exon 5 single-stranded RNA. 32 Stabilization of the stem-loop structure is sufficient to block U2AF65 binding and repress cTNT exon 5 inclusion in the absence of MBNL1. 32 Taken together with the evidence that MBNL1 binding alters the conformation of the cTNT RNA, this suggests that the mechanism of MBNLmediated repression is via the modulation of a structural element in the cTNT transcript.
Why then does the MBNL1-D5 isoform repress cTNT exon inclusion less efficiently than full length MBNL1 when it also binds with higher affinity to the cTNT RNA? There are three likely explanations for this discrepancy. First, the reduction of MBNL1-D5 alternative splicing activity may simply be explained by a relocalization of MBNL1 protein to the cytoplasm. The increase in inclusion of cTNT exons 4 and 5 (Fig. 6C) during heart development despite a continued presence of MBNL1 in the nucleus (Fig. 4C) , however, suggests that there may be an inherent loss of MBNL1 alternative splicing activity as well. Second, although MBNL1-D5 binds the RNA more tightly than full length MNBL1, it may bind the RNA in a different conformation. A conformational state that destabilizes or opens the stemloop might permit more U2AF65 to bind. Third, the explanation may be one of kinetics. The higher affinity of MBNL1-D5 for its target RNA may result in a slower release rate. If MBNL1-D5 remains associated with the intron after it is removed, less free MBNL1-D5 would be available to interact with as-yet-unspliced cTNT pre-mRNAs. Full length MBNL1 protein, on the other hand, would be predicted to have a faster off-rate, allowing it to recycle rapidly onto new transcripts. The apparent K d of full length MBNL1, although higher than that of MBNL1-D5, is still low enough to compete effectively with U2AF65, which was reported to have an apparent K d of approximately 0.3 μM on the same cTNT 50mer under similar binding conditions. 32 Interestingly, the inclusion of exon 5 in MBNL1 and MBNL2 transcripts increases in MBNL1 protein-deficient mice, 12 suggesting that the alternative splicing of MBNL pre-mRNAs may be regulated by an auto-feedback loop in which low MBNL1 levels lead to the production of MBNL1 isoforms with higher activity.
Consequences for cytoplasmic functions of MBNL proteins. The primary function ascribed to MBNL proteins has been the regulation of pre-mRNA alternative splicing in the nucleus, but growing evidence suggests that MBNL proteins have important cytoplasmic functions, too. The most compelling evidence is for MBNL2, which has been shown to regulate localization of integrin α3 mRNA in the cytoplasm to sites of focal adhesion for localized protein production. 33 MBNL1 has been shown to relocalize to stress granules in the cytoplasm under stress conditions, where it has been suggested that it might play a role in regulating mRNA stability or translatability. 34 Consistent with previously reported experiments using human MBNL1-GFP fusion proteins in skeletal muscle cells, 12 our data indicate that MBNL1 and MBNL2 proteins that include exon 5-encoded sequences are strictly nuclear, but exclusion of exon 5 redistributes a portion of the MBNL protein population to the cytoplasm in a cell type-independent manner (Figs. 4; and 7C  and D) . Thus, alternative splicing of exon 5 is a conserved mechanism for regulating subcellular localization of MBNL proteins
Discussion
Functional implications of MBNL1 exon 5 alternative splicing. It has been known for some time that alternative splicing of MBNL primary transcripts can give rise to a host of different MBNL protein isoforms, but the distribution of MBNL variants in vivo and the implications for MBNL function have not been fully determined. In this study, we report for the first time that alternative splicing of MBNL exon 5 undergoes an early developmental transition in the heart during cardiac morphogenesis that is conserved both between orthologous species (Figs. 2 and 3 ) and between paralogous genes (Fig. 7) . Our data indicate that inclusion or skipping of exon 5 regulates the subcellular localization, RNA binding affinity and alternative splicing activity of MBNL1 proteins.
Our demonstration that the inclusion of exon 5 increases the apparent K d of MBNL1 for cTNT RNA is a novel discovery. Kino et al. compared the binding activities of several deletion mutants, but tested only one natural splice variant, which did not include exon 5. 24 Similar truncated or long forms lacking exon 5 were subsequently used by others to compare the binding affinities of MBNL1 proteins on different RNA substrates. 26, 29 This is the first time that the binding affinities of naturally occurring MBNL1 isoforms have been compared.
Skipping of exon 5 preserves the open reading frame, and the 18 amino acids encoded by exon 5 (TQSAVKSLKRPLEATFDL) do not constitute a readily recognizable protein domain, nor do they contain any predicted functional motifs. The residues encoded by exon 5 lie immediately downstream of an alanine-rich region that is conserved in vertebrate MBNL1 and MBNL2 proteins. 25, 30 Although the function of this alanine-rich region is unknown, a similar alanine-rich region has been shown to be important for high affinity binding and oligomerization of another RNA binding protein, AUF1. 31 Analyses of a truncated MBNL1 protein have suggested that sequences in its C-terminal half, which includes the alanine-rich region, affect RNA binding affinity and possibly mediate homotypic protein interactions. 24, 29 Perhaps the residues encoded by MBNL1 exon 5 modulate the function of its alanine-rich region in mediating RNA binding and/or oligomerization. Interestingly, vertebrate MBNL3 proteins lack both the alanine-rich region and sequences paralogous to MBNL1 exon 5.
25,30
The ability of MBNL proteins to bind to their target RNAs is essential for their splicing activity. For example, mutations in a cTNT minigene that eliminate MBNL binding abolish repression of exon inclusion by MBNL. 16 A mechanism for MBNLmediated repression of cTNT exon 5 inclusion has been proposed. Using the same 50mer from cTNT intron 4 used in this study, a MBNL1 protein was shown to bind to a stem-loop structure in the cTNT RNA. 26 Analysis of the CD spectra with and without MBNL1 suggested that MBNL1 binding alters the structure of the cTNT RNA in such a way that base stacking is reduced. In a follow-up study, Warf and colleagues demonstrated that when MBNL1 binds the cTNT RNA, U2AF65 binding is competitively reduced and A complex formation is blocked. . All PCR products were resolved on 5% non-denaturing polyacrylamide gels, scanned by a Phosphorimager (Molecular Dynamics), and quantified using ImageQuant software.
Cell culture. Primary cardiomyocytes (1° CM) were isolated as previously described and grown in Minimum Essential Medium supplemented with 10% heat-inactivated horse serum, 5% chicken embryo extract with antibiotic-antimycotic additive. 38 COS-M6 cells were plated in high-glucose Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin.
Plasmids. Chicken MBNL1 and MBNL2 cDNAs were amplified by RT-PCR from embryonic day 8 brain RNA and cloned into pCR-Blunt II TOPO vector (Invitrogen) (MBNL1 primers were ATG GCC GTC AGC GTC ACG CCC ATC and CTA CAT CTG TGT AAC ATA CTT GTG; MBNL2 primers were ATG GCC TTG AAC GTT GCC CC and TTA GCA TGC AGT TTG TGG CAA TTC). Chicken MBNL1-D5 and MBNL2-D5 were generated by mega primer-directed PCR. MBNL1 and MBNL1-D5 open reading frames were subcloned into the pcDNA3.1HisC vector (Invitrogen) in-frame with the N-terminal His 6 /Xpress epitope tag. MBNL1 and MBNL1-D5 not just across species, but across paralogs as well. The purpose of the shift in exon 5 skipping during embryonic heart development may therefore be to generate a cytoplasmic pool of MBNL proteins to drive changes in the stability, localization, or translation of cytoplasmic mRNA targets.
In conclusion, we propose that the developmental stage and tissue-specific alternative splicing of MBNL transcripts plays an important role in regulating MBNL activities in vivo. 35) . Also, several organs were isolated from d14 embryos. Mouse embryos were obtained from timedpregnant Swiss Webster mice purchased from Taconic. Hearts were harvested from embryonic day 9 (E9), E12, E14 and E16 embryos, and other organs were harvested at E16. All animal procedures were performed under the oversight of the Institutional Animal Care and Use Committee and were in accordance with the recommendations of the American Veterinary Medical Association.
Materials and Methods
Animals
Western blots. Several pooled hearts from each time point were homogenized in protein loading buffer (0.64 mol/L TrisHCl, pH 6.8, 10% glycerol, 2% SDS, 5% BME) for total protein. Nuclear and cytoplasmic fractions were collected as previously described. 22 Total or nuclear and cytoplasmic protein (30 μg) samples were resolved by denaturing polyacrylamide gel electrophoresis (SDS-PAGE), transferred, and probed. MBNL1 protein was detected using the polyclonal anti-rabbit antibody A2764 (gift from Charles A. Thornton, University of Rochester, NY) at a dilution of 1:20,000. The efficacy of nuclear/cytoplasmic fractionation was confirmed using antibodies against hnRNPC and β-tubulin as previously described. 22 Protein integrity and equivalent loading was confirmed by Ponceau S staining.
Semi-quantitative RT-PCR analysis of endogenous alternative slicing and transcript levels. Total RNA from several pooled hearts from each time point, pooled non-cardiac organs, or transfected cells was extracted by the method of Chomcynski and Sacchi. 36 Semi-quantitative reverse transcription-PCR (RT-PCR) with 5'-end-labeled primer was carried out as previously described 37 with the following modifications: 250 ng of total RNA was used in the RT-PCR, and for analysis of chicken and mouse MBNL1 and mouse MBNL2 exon 5 alternative splicing, 100 ng of forward primer were used for 5' labeling. To evaluate the level of MBNL1 and 18S total transcripts, 5 μCi of [α-32 P]dCTP was added to the RT-PCR mix. Primers used for semi-quantitative RT-PCR analysis of MBNL and cTNT alternative slicing isoforms or MBNL1 target transcript levels are listed in Table 1 . Conditions were optimized for each primer set BL21-Star expression cells (Invitrogen), protein expression was induced with 0.25 mM IPTG at an OD 600 = 0.5-0.8 for 4 h or 6 h for MBNL1 and MBNL1-D5 isoforms, respectively, at 25°C. Cells were lysed under native condition with 1.5 mg/ml lysozyme followed by sonication in ice (3 x 30 sec) and proteins were purified using TALON Metal Affinity Resins (Clontech) according to the manufacturer's protocol, with 300 mM imidazole. After elution the recombinant proteins were dialyzed into storage buffer (50% glycerol, 500 mM NaCl, 20 mM Tris pH 7.7 and 5 mM BME) and stored at -20°C. The purity of the purified proteins was confirmed on 12.5% SDS-PAGE by staining with GelCode Blue Reagent (Pierce). RNA-based electrophoretic mobility shift assay (REMSA). A previously described human cTNT 50-mer oligonucleotide was used as the RNA probe. 26 The oligo, purchased from Integrated DNA Technologies, was 5'-end labeled using [γ-
32 P]ATP and purified using Micro Bio-Spin Columns (Bio-Rad Laboratories). REMSA was performed as described. 26 In brief, 20 fmol of labeled RNA probe were annealed at 95°C for 3 min and placed directly on ice for 20 min. Recombinant purified protein at concentrations ranging from 0 to 0.3 μM was added to the RNA probe in binding reaction buffer (175 mM NaCl, 5 mM MgCl 2 , 20 mM Tris pH 7.5, 1.25 mM BME, 12.5% glycerol, 2 mg/ml BSA and 0.1 mg/ml heparin) to a final volume of 10 μl and incubated for 20 min at room temperature. Five μl of the reaction was resolved by 3% acrylamide (37.5:1) and 0.5x TRIS borate buffer, run for 1 h at 4°C, 175 V, the gel was dried and subjected to autoradiography. The amount of radioactivity in the bands corresponding to the free and complexed RNA was measured using a PhosphorImager and ImageQuant Software. Apparent K d values were determined with GraphPad Prism3 Software (GraphPad Prism3 Software, Inc.).
Statistics. Data are reported as the mean ± standard error of the mean. Comparisons between means were performed via twotailed t-tests assuming unequal variances using Microsoft Excel software. Differences were considered statistically significant when p ≤ 0.05. cDNAs were also individually subcloned into the pEGFP-C1 vector (BD Biosciences Clontech) in-frame with the N-terminal EGFP open reading frame (GFP-MBNL1 and GFP-MBNL1-D5). MBNL2 and MBNL2-D5 cDNAs were likewise subcloned in pEGFP-C1 (GFP-MBNL2 and GFP-MBNL2-D5). Final constructs were verified by DNA sequencing.
Localization of GFP-MBNL1 isoforms. 1° CM and COS-M6 cells were transfected using Lipofectamine with Plus reagent (Invitrogen) or Fugene 6 (Roche Applied Science), respectively, with 2 μg of GFP-MBNL1, GFP-MBNL2, GFP-MBNL1-D5 or GFP-MBNL2-D5 plasmid, following the manufacturer's instructions. The expression of GFP fusion proteins was confirmed by western blot using an anti-GFP polyclonal antibody (Chemicon International, Inc.) at a dilution of 1:500. Cells were fixed at 18 h (COS-M6) or 16 h (1° CM) after transfection with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 1 h at room temperature. After washing twice with PBS, DAPI (Sigma) was added to the cells at a concentration of 1 μg/ml for 15 min at room temperature in the dark. The plates were rinsed with PBS four times, and visualized by fluorescence microscopy on a Leica DMIRB inverted microscope (Leica Microsystems, GmbH, Wetzlar, Germany).
Alternative splicing of cTNT minigene by MBNL1 isoforms. To monitor cTNT splicing by the two MBNL1 isoforms, 1° CM were transfected using Lipofectamine and Plus reagent with 250 ng of the chicken cTNT R35C minigene DNA 27 and 0 to 1.2 μg of Xpress-tagged MBNL1 or MBNL1-D5 expression plasmid. After 48 h the cells were harvested for extraction of total RNA or total protein. The extent of minigene exon inclusion was determined by RT-PCR analysis as described, 27 except 21 cycles of amplification were used due to the lower transfection efficiency of 1° CM. Expression of MBNL1 or MBNL1-D5 in R35C minigene experiments was assessed by western blot. Total protein samples were collected from transfected 1° CM plates by scraping cells in 250 μl of protein loading buffer and sonicating. Equal volumes of extracts (30 μl) were resolved on 10% SDS-PAGE and blotted with an anti-Xpress mouse monoclonal antibody (Invitrogen) at a dilution of 1:5,000. Equal protein loading was confirmed by western blot using anti-GAPDH mouse monoclonal antibody (Biogenesis, UK) at a dilution of 1:200,000.
Cloning and purification of bacterial recombinant proteins. Chicken MBNL1 and MBNL1-D5 open reading frames were cloned into pET-28a (+) vector (EMD Bioscience) in frame with His-tag coding sequence at the N-terminus. Using
